Literature DB >> 26427847

Operative Results and Clinical Features of Chronic Stanford Type B Aortic Dissection: Examination of 234 Patients Over 6 Years.

T Fujikawa1, S Yamamoto2, Y Sekine2, S Oshima2, R Kasai2, Y Mochida2, K Ozaki2, S Sasaguri2.   

Abstract

OBJECTIVE/
BACKGROUND: Recently, the indications for thoracic endovascular aortic repair (TEVAR) have been expanding, and the applicability of TEVAR for acute type B aortic dissection (TBAD) is proposed with regard to the high mortality of open surgery for chronic TBAD. TEVAR in the acute phase may lead to remodeling of the false lumen (FL), but it is controversial whether it completely resolves the aortic expansion in the chronic phase. In this study, operative results and the relationship between FL status and the time before surgical intervention were retrospectively analyzed.
METHODS: From January 2008 to September 2013, 234 patients underwent open surgery for chronic TBAD. Most patients were on left heart bypass. By considering Japanese aortic disease treatment guidelines and the smaller physique of Japanese patients, operative indications were aneurysm >50 mm in diameter or rapid aneurysm enlargement of >5 mm in a 6 month period.
RESULTS: In 180 cases, the FL was patent. The mean interval between onset of TBAD and operation was 61 ± 54 months. There was no significant difference between patients in the patent FL group and those in the thrombosed FL group (p = .44). Mean ratio of FL diameter to maximum aortic diameter (FL/AD) was 0.64 ± 0.21. There was no correlation between FL and AD before the operation (r = .12). Descending thoracic aortic replacement (DTAR) was performed in 127 cases and thoracic ascending aortic replacement (TAAR) in 107 cases (Crawford type I, n = 9; Crawford type II, n = 65; Crawford type III and IV, n = 22, respectively; Safi type V, n = 11). The overall operative mortality was 6.8%: 3.9% (5/127) for DTAR and 10.3% (11/107) for TAAR. The three year survival was 86.7, and the freedom from re-intervention rate was 97.0%.
CONCLUSION: Enlargement of uncomplicated TBAD in the chronic phase was poorly related to FL status and the results of open repair have improved. However, further prospective study is necessary.
Copyright © 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic dissection; Descending aorta thoraco-abdominal aorta; Open surgery; Stanford type B

Mesh:

Year:  2015        PMID: 26427847     DOI: 10.1016/j.ejvs.2015.07.012

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  5 in total

Review 1.  [Endovascular versus conventional vascular surgery - old-fashioned thinking? Part 1: interventions on the aorta].

Authors:  E S Debus; T Kölbel; D Manzoni; C-A Behrendt; F Heidemann; R T Grundmann
Journal:  Chirurg       Date:  2016-03       Impact factor: 0.955

2.  Open repair remains the gold standard.

Authors:  Jonathan C Hong; Joseph S Coselli
Journal:  JTCVS Tech       Date:  2021-01-26

3.  Descending thoracic aortic repair outcomes for chronic aortic dissection: a single-centre experience.

Authors:  Yoshitaka Yamane; Susumu Oshima; Kazumasa Ishiko; Makoto Okiyama; Tomohiro Hirokami; Yuki Hirai; Shigeru Sakurai; Kensuke Ozaki; Kenichi Yoshimura; Shinya Takahashi; Shin Yamamoto
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-09-09

4.  Retrospective analysis of factors associated with aortic remodeling in patients with Stanford type B aortic dissection after thoracic endovascular aortic repair.

Authors:  Biao Yu; Tangzhiming Li; Huadong Liu
Journal:  J Cardiothorac Surg       Date:  2021-07-07       Impact factor: 1.637

5.  Contemporary Management Strategies for Chronic Type B Aortic Dissections: A Systematic Review.

Authors:  Arnoud V Kamman; Hector W L de Beaufort; Guido H W van Bogerijen; Foeke J H Nauta; Robin H Heijmen; Frans L Moll; Joost A van Herwaarden; Santi Trimarchi
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.